Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.53 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.53 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.53 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.53 |
| ▸ | POLA1 | P09884 | 1/20 | 0.52 |
| ▸ | P2RY2 | P41231 | 6/20 | 0.51 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.51 |
| ▸ | P2RY14 | Q15391 | 4/20 | 0.48 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL20769291 | 1.00 | SLC28A1 (0.53) | SLC28A1SLC28A2SLC29A1SLC28A3POLA1 | |
| Phosphoramidic Acid SCHEMBL17439381 | 0.95 | SLC29A1 (0.51) | SLC28A1SLC28A2SLC29A1SLC28A3POLA1 | |
| SCHEMBL1763360 | 0.95 | SLC29A1 (0.57) | SLC28A1SLC28A2SLC29A1SLC28A3POLA1 | |
| SCHEMBL8749574 | 0.95 | SLC29A1 (0.57) | SLC28A1SLC28A2SLC29A1SLC28A3POLA1 | |
| SCHEMBL7876363 | 0.95 | SLC29A1 (0.57) | SLC28A1SLC28A2SLC29A1SLC28A3POLA1 | |
| SCHEMBL233416 | 0.95 | SLC29A1 (0.57) | SLC28A1SLC28A2SLC29A1SLC28A3POLA1 | |
| Hydrochloric Acid SCHEMBL29938288 | 0.94 | SLC29A1 (0.56) | SLC28A1SLC28A2SLC29A1SLC28A3POLA1 | |
| Phosphoric Acid SCHEMBL21751466 | 0.89 | SLC29A1 (0.55) | SLC28A1SLC28A2SLC29A1SLC28A3POLA1 | |
| Phosphoric Acid SCHEMBL21489124 | 0.86 | SLC28A1 (0.51) | SLC28A1SLC28A2SLC29A1SLC28A3POLA1 | |
| Phosphoric Acid SCHEMBL21489185 | 0.86 | SLC28A1 (0.51) | SLC28A1SLC28A2SLC29A1SLC28A3POLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11041151-B2 | RNA array compositions and methods | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2021-06-22 | — | — | US | disclosed |
| US-10167474-B2 | Cell-specific internalizing RNA aptamers against human CCR5 and uses therefore | CITY OF HOPE (US) | 2019-01-01 | — | — | US | disclosed |
| US-20180112211-A1 | RNA Array Compositions and Methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-04-26 | — | — | US | disclosed |
| US-20180080026-A1 | CELL-SPECIFIC INTERNALIZING RNA APTAMERS AGAINST HUMAN CCR5 AND USES THEREFORE | THE SCRIPPS RESEARCH INSTITUTE | 2018-03-22 | — | — | US | disclosed |
| US-9605266-B2 | Cell-specific internalizing RNA aptamers against human CCR5 and uses therefore | CITY OF HOPE (US) | 2017-03-28 | — | — | US | disclosed |
| US-20160193202-A1 | THERAPEUTIC TREATMENT FOR DRUG POISONING AND ADDICTION | ADISPELL, INC. | 2016-07-07 | — | — | US | disclosed |
| US-20160053265-A1 | CELL-SPECIFIC INTERNALIZING RNA APTAMERS AGAINST HUMAN CCR5 AND USES THEREFORE | THE SCRIPPS RESEARCH INSTITUTE | 2016-02-25 | — | — | US | disclosed |
| WO-2015023664-A2 | THERAPEUTIC TREATMENT FOR DRUG POISONING AND ADDICTION | ADISPELL, INC. (US) | 2015-02-19 | — | — | WO | disclosed |
| US-20140235505-A1 | RNA ARRAY COMPOSITIONS AND METHODS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-08-21 | — | — | US | disclosed |
| WO-2014011768-A1 | ANTI-ANXIETY TREATMENT | ADISPELL, INC. (US) | 2014-01-16 | — | — | WO | disclosed |
| US-5958691-A | DETECTION OF NUCLEIC ACID LIGANDS WITH MODIFIED NUCLEOTIDE TO TARGET GROUPS, SINGLE STRAND NUCLEIC ACIDS AND PARTITIONING THE NUCLEIC ACIDS, AMPLIFICATION | NEXSTAR PHARMACEUTICALS, INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5817635-A | RNA MOLECULES WITH CATALYTIC ACTIVITY | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 1998-10-06 | — | — | US | disclosed |
| US-5698687-A | RNA MOLECULE CONTAINING MODIFIED NUCLOSIDE | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 1997-12-16 | — | — | US | disclosed |
| US-5672695-A | GENETIC ENGINEERED RNA MOLECULE, ATLEAST ONE MODIFIED NUCLEOSIDE HAVING A HALO, AMINO, MONO OR DISUBSTITUTED AMINO AND AZIDE MODIFIER GROUPS REPLACING HYDROXY GROUP AT 2' POSITION OF DRIBOSE SUGAR; SHOWS CATALYTIC ACTIVITY | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 1997-09-30 | — | — | US | disclosed |
| US-5660985-A | CONTACTING MIXTURE OF MODIFIED SINGLE-STRANDED NUCLEIC ACIDS WITH TARGET MOLECULE, PARTITIONING THOSE WITH INCREASED AFFINITY, AMPLIFYING TO IDENTIFY LIGANDS OF TARGET MOLECULE | NEXSTAR PHARMACEUTICALS, INC. (US) | 1997-08-26 | — | — | US | disclosed |
| EP-0552178-B1 | MODIFIED RIBOZYMES | MAX PLANCK GESELLSCHAFT (DE) | 1997-01-02 | — | — | EP | disclosed |
| EP-0724647-A1 | NUCLEIC ACID LIGANDS AND IMPROVED METHODS FOR PRODUCING THE SAME | NeXstar Pharmaceuticals, Inc. (US) | 1996-08-07 | — | — | EP | disclosed |
| WO-1995007364-A1 | NUCLEIC ACID LIGANDS AND IMPROVED METHODS FOR PRODUCING THE SAME | NEXSTAR PHARMACEUTICALS, INC. (US) | 1995-03-16 | — | — | WO | disclosed |
| EP-0552178-A1 | MODIFIED RIBOZYMES. | MAX PLANCK GESELLSCHAFT (DE) | 1993-07-28 | — | — | EP | disclosed |
| WO-1992007065-A1 | MODIFIED RIBOZYMES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1992-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160193202-A1 | THERAPEUTIC TREATMENT FOR DRUG POISONING AND ADDICTION | CHRNG, CHRM3, CHRNA5 | SLC28A1 1247/4885SLC28A2 1195/4885SLC29A1 922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.